Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

• Status: Completed
• Trial end date: 2014-09-01

Summary

Primary Objective:

Participants Achieving an Objective Response Rate (Cheson 2007)

Secondary Objectives:

• Progression Free Survival

• Overall Survival

• Response Duration

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Maytansine; Rituximab